Abstract:We designed the killed swine influenza A virus (SwIAV) H1N2 antigen (KAg) with polyriboinosinic:polyribocytidylic acid [(Poly(I:C)] adsorbed corn-derived Nano-11 particle based nanovaccine called Nano-11-KAg+Poly(I:C), and evaluated its immune correlates in maternally derived antibody (MDA)-positive pigs against a heterologous H1N1 SwIAV infection. Immunologically, in tracheobronchial lymph nodes (TBLN) detected enhanced H1N2-specific cytotoxic T-lymphocytes (CTLs) in Nano-11-KAg+Poly(I:C) vaccinates, and in commercial vaccinates detected CTLs with mainly IL-17A + and early effector phenotypes specific to both H1N2 and H1N1 SwAIV. In commercial vaccinates, activated H1N2- and H1N1-specific IFNγ + &TNFα + , IL-17A + and central memory T-helper/Memory cells, and in Nano-11-KAg+Poly(I:C) vaccinates H1N2-specific central memory, IFNγ + and IFNγ + &TNFα + , and H1N1-specific IL-17A + T-helper/Memory cells were observed. Systemically, Nano-11-KAg+Poly(I:C) vaccine augmented H1N2-specific IFNγ + CTLs and H1N1-specific IFNγ + T-helper/Memory cells, and commercial vaccine boosted H1N2- specific early effector CTLs and H1N1-specific IFNγ + &TNFα + CTLs, as well as H1N2- and H1N1-specific T-helper/Memory cells with central memory, IFNγ + &TNFα + , and IL-17A + phenotypes. Remarkably, commercial vaccine induced an increase in H1N1-specific T-helper cells in TBLN and naive T-helper cells in both TBLN and peripheral blood mononuclear cells (PBMCs), while H1N1- and H1N2-specific only T-helper cells were augmented in Nano-11-KAg+Poly(I:C) vaccinates in both TBLN and PBMCs. Furthermore, the Nano-11-KAg+Poly(I:C) vaccine stimulated robust cross-reactive IgG and secretory IgA (SIgA) responses in lungs, while the commercial vaccine elicited high levels of serum and lung IgG and serum hemagglutination inhibition (HI) titers. In conclusion, despite vast genetic difference (77% in HA gene identity) between the vaccine H1N2 and H1N1 challenge viruses in Nano-11-KAg+Poly(I:C) vaccinates, compared to over 95% identity between H1N1 of commercial vaccine and challenge viruses, the virus load and macroscopic lesions in the lungs of both types of vaccinates were comparable, but the Nano-11-KAg+Poly(I:C) vaccine cleared the virus from the nasal passage better. These data suggested the important role played by Nano-11 and Poly(I:C) in the induction of polyfunctional, cross-protective cell-mediated immunity against SwIAV in MDA-positive pigs.

Microneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination Against Swine-Origin Influenza A (H1N1) in Mice.

Microneedle Delivery of Trivalent Influenza Vaccine to the Skin Induces Long-Term Cross-Protection

Immunization with a Low Dose of Hemagglutinin-Encoding Plasmid Protects Against 2009 H1N1 Pandemic Influenza Virus in Mice.

Microneedle Delivery of H5n1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice

Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus

Local Response to Microneedle-Based Influenza Immunization in the Skin

Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles

Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization

Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch

Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge

Enhanced Memory Responses to Seasonal H1n1 Influenza Vaccination of the Skin with the Use of Vaccine-Coated Microneedles

Intradermal Vaccination against Influenza with a STING-Targeted Nanoparticle Combination Adjuvant Induces Superior Cross-Protective Humoral Immunity in Swine Compared with Intranasal and Intramuscular Immunization

Intranasal Immunization With Recombinant Ha And Mast Cell Activator C48/80 Elicits Protective Immunity Against 2009 Pandemic H1n1 Influenza In Mice

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice

Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination

Improved Influenza Vaccination in the Skin Using Vaccine Coated Microneedles

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges

Intranasal Delivery of Inactivated Influenza Virus and Poly(I:C) Adsorbed Corn-Based Nanoparticle Vaccine Elicited Robust Antigen-Specific Cell-Mediated Immune Responses in Maternal Antibody Positive Nursery Pigs

Study on immunogenicity of recombinant lentivirus expressing trimeric HA of swine H1 N1 influenza virus

Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge

A Pandemic H1N1 Influenza Virus-Like Particle Vaccine Induces Cross-Protection in Mice